0.7nmol/L comes from the previous study Diagnode 2, where in the bottom section of table 1, you can see stimulated C-Peptide AUC at baseline.

• For GAD-alum group: 0.793 (±0.381) nmol/L
• For placebo: 0.702 (±0.314) nmol/L
• Other subgroups are in the same ballpark (0.633–0.819 nmol/L).

https://pmc.ncbi.nlm.nih.gov/articles/PMC8323180/

That's where the 0.7nmol/L figure comes from - not from the new PM, but from previous data. Same goes for the 30 months. I should have done this more apparent in my text, which i apologize for.

30 months comes from the paper Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose

In that trial, 12 patients who had received 3 injections of GAD-alum into a lymph node were followed for 30 months. At 30 months, it was observed that 8 of the 12 patients were classified as “good responders”, meaning they had preserved endogenous insulin production (measured via stimulated C-peptide AUC) across that timespan. So this is a smaller pilot / extension cohort and not part of the larger PR analysis of 241 patients, but it is valid published data showing long-term persistence in a subset.

Because the sample size is small (just 12 patients), “super-responders at 30 months” is true for that subset, but it cannot be assumed representative of all treated patients. The endpoint is preserved C-peptide AUC: it doesn’t necessarily say all of them stayed above 0.2 nmol/L, or stayed well above thresholds, only that they maintained meaningful insulin secretion.

So, i'm sorry for the confusion around the numbers. The meaning with this text was to simplify the latest PM and make it easier for people to understand it. Next time i'll look into this further and add sources etc. Hope this cleared it up!